JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

Raoul Bitar, Simon Halm, Christina Rossgoderer, Ladina P Gubser, Maeva Thévenaz, Yara Kreis, Carlos Nordt, Monika Visentini, Flora Moujaes, Andres Ort, Erich Seifritz, Marcus Herdener, Nathalie M. Rieser, Robin von Rotz, Etna Engeli, Franz X. Vollenweider, Katrin H. Preller

EClinicalMedicine March 14, 2025 DOI: 10.1016/j.eclinm.2025.103149 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Randomized controlled trial Peer reviewed
Population	Patients with alcohol use disorder
Topics	Addiction Psilocybin
Keywords	Randomized controlled trial Relapse prevention Psychotherapist Clinical trial
Citations	42
Key findings	Psilocybin-assisted therapy significantly reduced heavy drinking days compared to a control condition in patients with alcohol use disorder.

Abstract

Swiss National Science Foundation under the framework of Neuron Cofund, Swiss Neuromatrix Foundation, and Heffter Young Investigator Fellowship Award.

Explore topics

Addiction Psilocybin